Page last updated: 2024-12-08
lubimin
Description
lubimin: RN given refers to (5S-(5alpha(S*),6beta,8beta,10beta))-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
lubimin : A vetispirane sesquiterpenoid that consists of (2R,5S,6S,8S,10R)-8-hydroxy-10-methyl-2-(prop-1-en-2-yl)spiro[4.5]decane bearing a formyl substituent at position 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 442383 |
| CHEMBL ID | 2270658 |
| CHEBI ID | 27774 |
| SCHEMBL ID | 1835086 |
| MeSH ID | M0129078 |
Synonyms (17)
| Synonym |
|---|
| lubimin |
| C09700 |
| 35951-50-9 |
| (3r,5s,6r,8s,10s)-8-hydroxy-6-methyl-3-prop-1-en-2-ylspiro[4.5]decane-10-carbaldehyde |
| unii-sic6883o43 |
| spiro(4.5)decane-6-carboxaldehyde, 8-hydroxy-10-methyl-2-(1-methylethenyl)-, (5s-(5alpha(s*),6beta,8beta,10beta))- |
| sic6883o43 , |
| CHEBI:27774 , |
| (2r,5s,6s,8s,10r)-8-hydroxy-10-methyl-2-(prop-1-en-2-yl)spiro[4.5]decane-6-carbaldehyde |
| (2r,5s,6s,8s,10r)-8-hydroxy-2-isopropenyl-10-methylspiro[4.5]decane-6-carbaldehyde |
| CHEMBL2270658 |
| SCHEMBL1835086 |
| spiro(4.5)decane-6-carboxaldehyde, 8-hydroxy-10-methyl-2-(1-methylethenyl)-, (2r,5s,6s,8s,10r)- |
| spiro(4.5)decane-6-carboxaldehyde, 8-hydroxy-10-methyl-2-(1-methylethenyl)-, (5s-(5.alpha.(s*),6.beta.,8.beta.,10.beta.))- |
| Q27103322 |
| DTXSID80957361 |
| 8-hydroxy-10-methyl-2-(prop-1-en-2-yl)spiro[4.5]decane-6-carbaldehyde |
Roles (2)
| Role | Description |
|---|
| antifungal agent | An antimicrobial agent that destroys fungi by suppressing their ability to grow or reproduce. |
| phytoalexin | A toxin made by a plant that acts against an organism attacking it. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (1)
| Class | Description |
|---|
| vetispirane sesquiterpenoid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1101631 | Antifungal activity against Fusarium oxysporum f. sp. melongenae assessed as spore germination rate at 100 ppm relative to untreated control | 2001 | Bioscience, biotechnology, and biochemistry, Aug, Volume: 65, Issue:8
| Structural confirmation of 15-norlubiminol and 15-norepilubiminol, isolated from Solanum aethiopicum, by chemical conversion from lubimin and epilubimin, and their antifungal activity. |
| AID1101630 | Antifungal activity against Verticillium dahliae assessed as spore germination rate at 100 ppm relative to untreated control | 2001 | Bioscience, biotechnology, and biochemistry, Aug, Volume: 65, Issue:8
| Structural confirmation of 15-norlubiminol and 15-norepilubiminol, isolated from Solanum aethiopicum, by chemical conversion from lubimin and epilubimin, and their antifungal activity. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (4)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 2 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 21.83
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 21.83 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.32 (4.65) | | Search Engine Demand Index | 18.60 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |